Rewriting Cancer's Rules

The Protein-Destroying Therapies Entering Human Trials

Article Navigation

The Undruggable Problem

For decades, cancer treatment resembled a molecular arms race. Scientists developed inhibitors to block cancer-causing proteins, but tumors evolved workarounds. Many critical cancer drivers lacked binding pockets for conventional drugs, earning the label "undruggable." Enter targeted protein degradation (TPD)—a revolutionary approach that doesn't just block proteins but eliminates them entirely. By hijacking the cell's natural disposal systems, TPD turns cancer's survival mechanisms against itself 1 4 .

In 2025, this field has exploded: over 30 protein degraders are in clinical trials, with three reaching Phase III. This represents a paradigm shift from occupancy-driven pharmacology (inhibitors) to event-driven pharmacology (degraders), where a single degrader molecule can eliminate hundreds of disease-causing proteins 1 6 .

How Protein Degradation Therapies Work: Molecular Matchmakers

The Ubiquitin-Proteasome System: Cellular Recycling

Ubiquitin tagging

Specialized enzymes attach ubiquitin molecules to unwanted proteins.

Proteasome breakdown

The proteasome complex recognizes tagged proteins and shreds them into reusable fragments.

Recycling

Components are repurposed for new protein synthesis 1 6 .

PROTACs: Precision Destroyers

PROteolysis TArgeting Chimeras (PROTACs) are bifunctional molecules with three key components:

  • Target-binding warhead: Binds the cancer-causing protein (e.g., estrogen receptor in breast cancer).
  • E3 ligase ligand: Recruits the cell's ubiquitin-tagging machinery.
  • Chemical linker: Connects both ends at optimal length for precise protein-E3 ligase interaction 1 4 6 .

Once a PROTAC brings the target protein and E3 ligase together, the protein is ubiquitinated and delivered to the proteasome for destruction. Unlike inhibitors, PROTACs are catalytic—they can act repeatedly, degrading multiple protein copies 6 .

PROTACs in Phase III Clinical Trials (2025 Update) 2

Drug Name Target Indication Key Trial Findings
Vepdegestrant (ARV-471) Estrogen Receptor ER+/HER2- Advanced Breast Cancer Improved progression-free survival vs. fulvestrant in ESR1-mutant patients (HR: <0.60)
BMS-986365 (CC-94676) Androgen Receptor Metastatic Prostate Cancer 55% PSA30 response at 900mg dose; median rPFS: 8.3 months
BGB-16673 BTK Relapsed/Refractory CLL 78% overall response rate in Phase I

Why Degraders Outperform Inhibitors: Key Advantages

Undruggable Targets

Degraders don't require traditional binding pockets. They target protein surfaces or interfaces previously considered "undruggable," like transcription factors 4 6 .

Resistance Prevention

Inhibitors leave proteins intact, enabling mutations that restore function. Degraders remove the entire protein, reducing escape routes 4 .

Lower Dosing

Event-driven action allows sub-stoichiometric activity—lower doses reduce off-target toxicity 1 .

Targeting Multiple Mutants

A single degrader can eliminate various mutant forms of a protein (e.g., AR mutants in prostate cancer) 1 2 .

Spotlight Experiment: Enzyme Discovery That Supercharges Immunotherapy

Background: The Lymphatic Paradox

Lymphatic vessels near tumors have a dual role: they can promote metastasis but also transport immune cells. Researchers at the University of Geneva sought to understand how lymphatic cells influence anti-tumor immunity 3 .

Methodology: Decoding CH25H's Role
  1. Gene Expression Profiling: Compared lymphatic endothelial cells from melanoma vs. healthy mouse skin.
  2. Human Validation: Analyzed CH25H levels in melanoma patient samples with varying lymphatic vessel density.
  3. Genetic Knockout: Deleted CH25H gene in mouse lymphatic cells.
  4. Metabolite Measurement: Tracked 25-hydroxycholesterol (25-HC) levels in tumors.
  5. Immunotherapy Testing: Combined CH25H modulation with anti-PD-1 checkpoint inhibitors 3 .
Results: A Biomarker and Booster
  • Biomarker Potential: Melanoma patients with high CH25H levels had better survival, especially those receiving immunotherapy.
  • Immune Activation: CH25H produces 25-HC, which counteracts tumor immunosuppressive factors.
  • Knockout Consequences: CH25H deletion reduced 25-HC by >60%, suppressed T-cell activity, and accelerated tumor growth.
  • Therapeutic Synergy: Vaccinating mice increased CH25H and 25-HC, enhancing immunotherapy responses 3 .

CH25H Impact on Tumor Immunity 3

Condition 25-HC Levels T-cell Activation Tumor Growth
Normal CH25H expression High Robust Suppressed
CH25H knockout Low Weak Accelerated
CH25H boost + anti-PD-1 Very High Enhanced Arrested
Key Insight: CH25H is a promising biomarker for immunotherapy success and a candidate for combination therapies.

The Scientist's Toolkit: Building the Next Generation of Degraders

Essential Reagents in Protein Degrader Development 1 5 6

Reagent/Material Function Example/Application
E3 Ligase Ligands Recruit ubiquitin machinery to target VHL, CRBN, MDM2 ligands (e.g., for KT-253)
Linker Libraries Optimize distance/orientation of PROTAC ends PEG, alkyl, or triazole-based spacers
Ubiquitination Assays Confirm target protein tagging Ubiquitin remnant profiling by mass spec
Cryo-EM Structures Visualize ternary target-PROTAC-E3 complexes PROTAC®-VHL-AR complex (Arvinas)
Spray-Dried Dispersions Enhance solubility/bioavailability Used for ARV-110 formulation
rel-Biperiden-d5C21H29NO
LXR antagonist 2C34H40N2O5S
Decenedioic acid6048-93-7C10H16O4
Glutaminase-IN-1C26H24F3N7O3Se
Undecyl benzoate6316-30-9C18H28O2
Innovation Highlight

Companies like WuXi AppTec have synthesized >188,000 degrader compounds. For one client, they redesigned a 24-step synthesis into 16 steps while developing a spray-dried dispersion to boost bioavailability—delivering the material 2 months early 5 .

Beyond PROTACs: The Expanding Universe of Degradation

Molecular Glues

(e.g., lenalidomide): Reshape E3 ligases to capture new targets without a linker 6 8 .

LYTACs

Degrade extracellular proteins using lysosomal pathways via cell-surface receptors.

AUTACs

Tag targets with "kiss-of-death" molecules resembling damaged proteins.

Emerging Targets

SMYD5 inhibitors (gastric cancer) and USP37 blockers (DNA replication stress) show preclinical promise 7 .

Conclusion: From Lab to Clinic – A New Era Dawns

The first PROTAC drug application (vepdegestrant) is under FDA review, with a decision expected in 2025. While challenges remain—oral bioavailability, tissue specificity, resistance mechanisms—the clinical data so far are compelling. As Dr. Pawel Mazur notes, enzymes like SMYD5 represent "an excellent drug target" with minimal toxicity to normal tissues 7 .

Protein degraders exemplify a fundamental shift: from blocking cancer's machinery to dismantling it entirely. As these molecules advance, they offer hope for patients with resistant cancers and a blueprint for targeting the "undruggable" genome.

"This isn't just a new drug class—it's a new way to think about therapeutics."

Industry Leader, WuXi AppTec 5

References